CTMXCytomX Therapeutics, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 13885
Ticker: CTMX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2015-10-08
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CTMX

Detail

Enriched 2026-08-14 20:47

Market cap: $760,468,501.16
Shares outstanding (class): 217,702,919
Shares outstanding (weighted): 217,899,284
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 69
Location: SOUTH SAN FRANCISCO, CA
Homepage: https://www.cytomx.com
Description: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Market cap and share counts drift.

Funds holding this security

27 funds · 29 positions · $88.16M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$30.70M	0.00%	6,531,787 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$21.20M	0.29%	4,511,036 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$9.37M	0.01%	1,992,904 NS	FIGI
Fidelity U.S. Equity Central Fund Fidelity Central Investment Portfolios LLC	—	$4.70M	0.02%	1,000,000 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$4.64M	0.06%	987,397 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$4.23M	0.27%	900,000 NS	FIGI
VIP Health Care Portfolio Variable Insurance Products Fund IV	—	$4.04M	0.40%	860,000 NS	FIGI
First Trust Dow Jones Select MicroCap Index Fund First Trust Exchange-Traded Fund	FDM	$2.67M	1.18%	568,562 NS	FIGI
VIP Stock Selector Portfolio Variable Insurance Products Fund	—	$1.02M	0.02%	218,000 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.02M	0.00%	217,485 NS	FIGI
BlackRock Health Sciences Term Trust —	—	$1.01M	0.10%	215,748 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$543.5K	0.00%	115,646 NS	FIGI
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX… VANGUARD INSTITUTIONAL INDEX FUNDS	—	$431.1K	0.00%	91,733 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$380.1K	0.02%	80,880 NS	FIGI
VIP Disciplined Small Cap Portfolio Variable Insurance Products Fund II	—	$378.8K	0.07%	80,596 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCTMX
FIGI_COMPOSITEBBG001J472L3
FIGI_SHARE_CLASSBBG001V0GS49
CIK0001501989
ISINUS23284F1057
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.9
Model: deepseek
Rationale: CytomX is a clinical-stage biopharmaceutical company developing antibody-based therapies, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.